table of content
1 Study Coverage
1.1 Hemoglobinopathies Drugs Product Introduction
1.2 Global Hemoglobinopathies Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global Hemoglobinopathies Drugs Sales in US$ Million for the Year 2017-2028
1.2.2 Global Hemoglobinopathies Drugs Sales in Volume for the Year 2017-2028
1.3 United States Hemoglobinopathies Drugs Outlook 2017 VS 2022 VS 2028
1.3.1 United States Hemoglobinopathies Drugs Sales in US$ Million for the Year 2017-2028
1.3.2 United States Hemoglobinopathies Drugs Sales in Volume for the Year 2017-2028
1.4 Hemoglobinopathies Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Hemoglobinopathies Drugs in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Hemoglobinopathies Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Hemoglobinopathies Drugs Market Dynamics
1.5.1 Hemoglobinopathies Drugs Industry Trends
1.5.2 Hemoglobinopathies Drugs Market Drivers
1.5.3 Hemoglobinopathies Drugs Market Challenges
1.5.4 Hemoglobinopathies Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Hemoglobinopathies Drugs Market Segment by Type
2.1.1 Thalassemia Therapy
2.1.2 Sickle Cell Disease(SCD) Therapy
2.1.3 Other Therapy
2.2 Global Hemoglobinopathies Drugs Market Size by Type
2.2.1 Global Hemoglobinopathies Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Hemoglobinopathies Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Hemoglobinopathies Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Hemoglobinopathies Drugs Market Size by Type
2.3.1 United States Hemoglobinopathies Drugs Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Hemoglobinopathies Drugs Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Hemoglobinopathies Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Hemoglobinopathies Drugs Market Segment by Application
3.1.1 Alpha Thalassemia
3.1.2 Beta thalassemia
3.1.3 Sickle Cell Disease
3.1.4 Hb Variants Diseases
3.2 Global Hemoglobinopathies Drugs Market Size by Application
3.2.1 Global Hemoglobinopathies Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Hemoglobinopathies Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Hemoglobinopathies Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Hemoglobinopathies Drugs Market Size by Application
3.3.1 United States Hemoglobinopathies Drugs Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Hemoglobinopathies Drugs Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Hemoglobinopathies Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Hemoglobinopathies Drugs Competitor Landscape by Company
4.1 Global Hemoglobinopathies Drugs Market Size by Company
4.1.1 Top Global Hemoglobinopathies Drugs Manufacturers Ranked by Revenue (2021)
4.1.2 Global Hemoglobinopathies Drugs Revenue by Manufacturer (2017-2022)
4.1.3 Global Hemoglobinopathies Drugs Sales by Manufacturer (2017-2022)
4.1.4 Global Hemoglobinopathies Drugs Price by Manufacturer (2017-2022)
4.2 Global Hemoglobinopathies Drugs Concentration Ratio (CR)
4.2.1 Hemoglobinopathies Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Hemoglobinopathies Drugs in 2021
4.2.3 Global Hemoglobinopathies Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Hemoglobinopathies Drugs Manufacturing Base Distribution, Product Type
4.3.1 Global Hemoglobinopathies Drugs Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Hemoglobinopathies Drugs Product Type
4.3.3 Date of International Manufacturers Enter into Hemoglobinopathies Drugs Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Hemoglobinopathies Drugs Market Size by Company
4.5.1 Top Hemoglobinopathies Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States Hemoglobinopathies Drugs Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Hemoglobinopathies Drugs Sales by Players (2020, 2021 & 2022)
5 Global Hemoglobinopathies Drugs Market Size by Region
5.1 Global Hemoglobinopathies Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Hemoglobinopathies Drugs Market Size in Volume by Region (2017-2028)
5.2.1 Global Hemoglobinopathies Drugs Sales in Volume by Region: 2017-2022
5.2.2 Global Hemoglobinopathies Drugs Sales in Volume Forecast by Region (2023-2028)
5.3 Global Hemoglobinopathies Drugs Market Size in Value by Region (2017-2028)
5.3.1 Global Hemoglobinopathies Drugs Sales in Value by Region: 2017-2022
5.3.2 Global Hemoglobinopathies Drugs Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Hemoglobinopathies Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Hemoglobinopathies Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Hemoglobinopathies Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Hemoglobinopathies Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Hemoglobinopathies Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Hemoglobinopathies Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Hemoglobinopathies Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Hemoglobinopathies Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Hemoglobinopathies Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Hemoglobinopathies Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE
7 Company Profiles
7.1 Gamida Cell
7.1.1 Gamida Cell Corporation Information
7.1.2 Gamida Cell Description and Business Overview
7.1.3 Gamida Cell Hemoglobinopathies Drugs Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Gamida Cell Hemoglobinopathies Drugs Products Offered
7.1.5 Gamida Cell Recent Development
7.2 Alnylam Pharmaceuticals
7.2.1 Alnylam Pharmaceuticals Corporation Information
7.2.2 Alnylam Pharmaceuticals Description and Business Overview
7.2.3 Alnylam Pharmaceuticals Hemoglobinopathies Drugs Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Alnylam Pharmaceuticals Hemoglobinopathies Drugs Products Offered
7.2.5 Alnylam Pharmaceuticals Recent Development
7.3 Biogen Idec
7.3.1 Biogen Idec Corporation Information
7.3.2 Biogen Idec Description and Business Overview
7.3.3 Biogen Idec Hemoglobinopathies Drugs Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Biogen Idec Hemoglobinopathies Drugs Products Offered
7.3.5 Biogen Idec Recent Development
7.4 Sangamo BioSciences Inc.
7.4.1 Sangamo BioSciences Inc. Corporation Information
7.4.2 Sangamo BioSciences Inc. Description and Business Overview
7.4.3 Sangamo BioSciences Inc. Hemoglobinopathies Drugs Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Sangamo BioSciences Inc. Hemoglobinopathies Drugs Products Offered
7.4.5 Sangamo BioSciences Inc. Recent Development
7.5 Genetix Pharmaceuticals/Bluebird Bio
7.5.1 Genetix Pharmaceuticals/Bluebird Bio Corporation Information
7.5.2 Genetix Pharmaceuticals/Bluebird Bio Description and Business Overview
7.5.3 Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Products Offered
7.5.5 Genetix Pharmaceuticals/Bluebird Bio Recent Development
7.6 Global Blood Therapeutics Inc.
7.6.1 Global Blood Therapeutics Inc. Corporation Information
7.6.2 Global Blood Therapeutics Inc. Description and Business Overview
7.6.3 Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Products Offered
7.6.5 Global Blood Therapeutics Inc. Recent Development
7.7 Pfizer Inc.
7.7.1 Pfizer Inc. Corporation Information
7.7.2 Pfizer Inc. Description and Business Overview
7.7.3 Pfizer Inc. Hemoglobinopathies Drugs Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Pfizer Inc. Hemoglobinopathies Drugs Products Offered
7.7.5 Pfizer Inc. Recent Development
7.8 Mast Therapeutics
7.8.1 Mast Therapeutics Corporation Information
7.8.2 Mast Therapeutics Description and Business Overview
7.8.3 Mast Therapeutics Hemoglobinopathies Drugs Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Mast Therapeutics Hemoglobinopathies Drugs Products Offered
7.8.5 Mast Therapeutics Recent Development
7.9 Emmaus Life Sciences, Inc.
7.9.1 Emmaus Life Sciences, Inc. Corporation Information
7.9.2 Emmaus Life Sciences, Inc. Description and Business Overview
7.9.3 Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Products Offered
7.9.5 Emmaus Life Sciences, Inc. Recent Development
7.10 Prolong Pharmaceuticals
7.10.1 Prolong Pharmaceuticals Corporation Information
7.10.2 Prolong Pharmaceuticals Description and Business Overview
7.10.3 Prolong Pharmaceuticals Hemoglobinopathies Drugs Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Prolong Pharmaceuticals Hemoglobinopathies Drugs Products Offered
7.10.5 Prolong Pharmaceuticals Recent Development
7.11 Celgene Corporation
7.11.1 Celgene Corporation Corporation Information
7.11.2 Celgene Corporation Description and Business Overview
7.11.3 Celgene Corporation Hemoglobinopathies Drugs Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Celgene Corporation Hemoglobinopathies Drugs Products Offered
7.11.5 Celgene Corporation Recent Development
7.12 HemaQuest Pharmaceuticals
7.12.1 HemaQuest Pharmaceuticals Corporation Information
7.12.2 HemaQuest Pharmaceuticals Description and Business Overview
7.12.3 HemaQuest Pharmaceuticals Hemoglobinopathies Drugs Sales, Revenue and Gross Margin (2017-2022)
7.12.4 HemaQuest Pharmaceuticals Products Offered
7.12.5 HemaQuest Pharmaceuticals Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Hemoglobinopathies Drugs Industry Chain Analysis
8.2 Hemoglobinopathies Drugs Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Hemoglobinopathies Drugs Distributors
8.3 Hemoglobinopathies Drugs Production Mode & Process
8.4 Hemoglobinopathies Drugs Sales and Marketing
8.4.1 Hemoglobinopathies Drugs Sales Channels
8.4.2 Hemoglobinopathies Drugs Distributors
8.5 Hemoglobinopathies Drugs Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
